Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Trial Identifier: D419SC00001
Sponsor: AstraZeneca
NCTID:: NCT02658214
Start Date: April 2016
Primary Completion Date: November 2019
Study Completion Date: November 2019
Condition: Cancer - Other; Esophageal cancer; Ovarian Cancer; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Japanese Translation
Korean Translation

Trial Locations

Country Location
Japan Chuo-ku, Japan, 104-0045
Japan Kashiwa, Japan, 277-8577
South Korea Seoul, South Korea, 03080
South Korea Seoul, South Korea, 03722
South Korea Seoul, South Korea, 135-710
South Korea Seoul, South Korea, 05505